Spebrutinib

N/A

Report date: 2024/01/23 20:00:33
NME

Base Information

Drug NameSpebrutinib
Drug Alias Nameespebrutinib司培替尼spebrutinibum司培卢替尼CC-292 +[6] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsArthritis, RheumatoidWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, Diffuse +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesItaly +[6] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCelgene Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCelgene Corp
Active IndicationsN/A
Inactive IndicationsArthritis, RheumatoidWaldenstrom MacroglobulinemiaLymphoma, Large B-Cell, Diffuse +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG